Abbvie Sp. z o.o. secures contract for Pharmaceutical products - Delivery of a medicinal product containing the active substance Mirvetuximabum soravtansinum referred under the B50 drug program Treatment of patients with ovarian cancer, fallopian tube cancer or peritoneal cancer

Poland, Oct. 27 -- Poland based Abbvie Sp. z o.o. has secured contract from Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie for Pharmaceutical products - Delivery of a medicinal product containing the active substance Mirvetuximabum soravtansinum referred under the B50 drug program Treatment of patients with ovarian cancer, fallopian tube cancer or peritoneal cancer. The value of the contract is worth 181439896 PLN.

Published by HT Digital Content Services with permission from Pivotal Sources....